The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hopefully we’ll get an update on the 7th regarding resubmission and possible funding
Agreed re fundraiser, very clumsy from now departed CEO. Would be interested in your or anyone else’s views on the SMC report and/or insight into how SMC operates.
Hard to foresee quite the hammering this one got this year imo.
With them being under 10p on the offer now it seems more instinctual to look for opps from growth in sales than to be negative over a possible funding shortfall so wanted to say thanks for the posts below as sniffing around for a position before the Sept update and the opinions here have been most useful.
Think most of us didn't foresee this share price action.
Company seem to have shot themselves in the foot by announcing that there will be funding shortfall following the Scottish decision. They should have raised the funds rather than make the announcement; a small placement and a Primary bid offer like others have done.
It's not like they attempted to raise but didn't succeed so informed the market.
I Thought most of the cash they raised was to fund the new trial and the US trial. so if they are burning cash it's paying for that. The problem with the SMC is a bummer but shouldn't cause that much of a problem they already stated that some places that usually follow their lead aren't so the situation is probably better than they first anticipated, I just wish they'd come out and say something positive on that subject.
Well, if they have 12 months cash I reckon most companies in this position would be looking to sure up cash position 6 months before they run out. If I knew there was to be no raise in next 6 months I would be a buyer of at least 100,000 shares, as new deals or progress with products could see a nice rise. As it is with no such assurances I could just be chucking 15% down the drain in the next week or so. Far safer just to wait for the funding, whatever it is, to be confirmed.
If you look at their 6 months results to 31/12/2021 (the most recent we have - we only have a trading update for the following 6 months), there is £5,889k expenditure on R+D, £3,069k on selling and distribution expenses, and £1,794 admin. I'd like to see the admin expenses lower, sure. But the lion's share of their cash burn is R+D. It's this that was fully funded by existing sales until the Scottish problem appeared. I don't mind them burning cash if it's them developing their pipeline of development, because that's the business plan. But I'd like to know how short the Scots have left them, and to have some sense of the scale of the raise or loan they'll need.
The problem is they are burning through cash. £16m will only cover 12 months worth of working capital. The current landscape is not favourable to companies who don't have a handle on cash control/generation so this will likely be subdued until there's a clearer understanding of how DNL will resolve their financing
Absolutely. So to summarise, todays pitiful sp is totally self inflicted. Even if Bungay had said in his comments todays results mean further funding would not be required in the short term this would be 50%+ up. The fact no comment was made leaves the Sword of Damocles dangling right over the buy button.
What they actually said was that the Scottish Medicines Consortium not recommending Efmody for NHS automatic reimbursement when treating CAH meant that further funding would be needed to reach profitability. Many pharmaceutical companies at this stage of development are not yet profitable. They reached the rare point a couple of years back where they had been able to say that they had enough revenue forecast from the drugs they had approved to get them through to profitability without further cash injection. The Scots meant they had to back-pedal on that one. But the amount of revenue they've lost from Scotland (and others who take their cue from Scotland) will be small relative to their other income, so it's not as if it's suddenly become a cash sinkhole. It's just that they no longer have a clear runway all the way.
So all they said is that they'll need some funds, from some source, at some point, and they'd look into their options, including the possibility of a non-dilutive placing. Nothing urgent (the results today show they have funds for the next 12 months). And not on a desparate scale.
When they explained all this, the share price was 33.5p. It dropped 50% on that day to 17p. It's now lower still. There's no way that particular detail justified that size of drop. Today's results show this continues to be a healthy business with approved drugs generating meaningful revenues. Hopefully it will now start to get back to a more appropriate market cap.
No idea, its just they said they needed one. Baffles me.
With £16m cash, why would they need a placing with any urgency?
Hopefully they will use this rise to forward sell the placing that everyone has been worried about for months now and we can get it out of the way. Maybe even get a loan, unlikely as that may be.